STAAR Surgical Co
NASDAQ:STAA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
26.14
52.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one STAA stock under the Base Case scenario is 22.19 USD. Compared to the current market price of 26.68 USD, STAAR Surgical Co is Overvalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
STAAR Surgical Co
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for STAA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
STAAR Surgical Co
Balance Sheet Decomposition
STAAR Surgical Co
Current Assets | 397.1m |
Cash & Short-Term Investments | 236m |
Receivables | 108m |
Other Current Assets | 53.2m |
Non-Current Assets | 140.5m |
PP&E | 119.6m |
Intangibles | 1.8m |
Other Non-Current Assets | 19.1m |
Current Liabilities | 66.3m |
Accounts Payable | 14.7m |
Accrued Liabilities | 25.7m |
Other Current Liabilities | 26m |
Non-Current Liabilities | 43.1m |
Other Non-Current Liabilities | 43.1m |
Earnings Waterfall
STAAR Surgical Co
Revenue
|
341.2m
USD
|
Cost of Revenue
|
-72.6m
USD
|
Gross Profit
|
268.7m
USD
|
Operating Expenses
|
-243m
USD
|
Operating Income
|
25.7m
USD
|
Other Expenses
|
-3.9m
USD
|
Net Income
|
21.8m
USD
|
Free Cash Flow Analysis
STAAR Surgical Co
USD | |
Free Cash Flow | USD |
STAA Profitability Score
Profitability Due Diligence
STAAR Surgical Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
STAAR Surgical Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
STAA Solvency Score
Solvency Due Diligence
STAAR Surgical Co's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
STAAR Surgical Co's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STAA Price Targets Summary
STAAR Surgical Co
According to Wall Street analysts, the average 1-year price target for STAA is 43.84 USD with a low forecast of 27.27 USD and a high forecast of 63 USD.
Dividends
Current shareholder yield for STAA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
STAA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company is headquartered in Lake Forest, California and currently employs 692 full-time employees. The company is a manufacturer of lenses used worldwide in corrective or refractive surgery. The company sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux and Italy. Its manufacturing facility in Monrovia, California, makes the Visian implantable Collamer lens product family, including the EVO Visian ICL, preloaded silicone cataract intraocular lenses and injector systems. Its manufacturing facility in Brugg, Switzerland, operates an administrative, distribution and operational through its subsidiary, STAAR Surgical AG. The company operates administrative and distribution facilities in Japan through its subsidiary, STAAR Japan Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one STAA stock under the Base Case scenario is 22.19 USD.
Compared to the current market price of 26.68 USD, STAAR Surgical Co is Overvalued by 17%.